Evidence map›Paper›PMID 40672101›Full record

ArticleJournal of gastrointestinal oncology2025

Molecular characterisation of Mozambican patients diagnosed with colorectal adenocarcinoma.

Carlos Selemane, Dylan Ferreira, Isabel Veiga, Patrícia Rocha, Luisa Jamisse, Landim Buane, Assucena Guisseve, Carla Carrilho, Mamudo Ismail, Manuel R Teixeira and 1 more

Abstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Carlos SelemaneDepartment of Surgery, Hospital Central Maputo, Maputo, Mozambique.
Dylan Ferreira *Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal.
Isabel Veiga *Department of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal.
Patrícia RochaDepartment of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal.
Luisa JamisseDepartment of Pathology, Hospital Central Maputo, Maputo, Mozambique.
Landim BuaneDepartment of Pathology, Hospital Central Maputo, Maputo, Mozambique.
Assucena GuisseveDepartment of Pathology, Hospital Central Maputo, Maputo, Mozambique.
Carla CarrilhoDepartment of Pathology, Hospital Central Maputo, Maputo, Mozambique.
Mamudo IsmailDepartment of Pathology, Hospital Central Maputo, Maputo, Mozambique.
Manuel R TeixeiraResearch Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal.
Lúcio Lara SantosResearch Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) represents a major healthcare problem worldwide, with significant impact in more unfavourable populations. Reports sustain an increased frequency of cases in these populations; however, the real scale remains to be fully disclosed. Data unveil that CRC in Africa manifests at younger age and in advanced stages of the disease that, in combination with scarce clinical strategies to manage patient treatment, leads to high rates of mortality. In this study, we aim to address the mutation landscape of Mozambican CRC tumours to improve the patient clinical management, focusing on Methods: A patient sample set of 30 CRC tumours from Mozambican patients was used to assess mutations in Results: Our results, opposing to previous reports published on African or African descent populations, reveal a predominance of mutations in KRAS and overexpression of p53 protein, with much lower mutation frequencies in the remaining genes. Conclusions: Identification of the mutational pattern of Mozambican CRC patients can help Mozambican clinicians better optimise treatment planning and therefore patient's outcome. Promising results obtained in our study, allied to scarcity of molecular data from Mozambican CRC patients, make imperative to enlarge our patient sample set to obtain more clinicopathological data and demographic/ancestry information.

Indexed as

Colorectal cancer (CRC)KRASMozambiquemutationsp53 protein

Identifiers

PMID40672101
PMCPMC12261019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.